Open House - Global Healthcare 2022: Belluscura plc | Edison Group
Belluscura is a publicly traded UK company listed on the AIM submarket of the London Stock Exchange (AIM: BELL). Belluscura focuses on developing and commercialising innovative oxygen enrichment technologies that span broad industries and therapies.
-
Robert “Bob” Rauker, Chief Executive Officer, Belluscura plc
Bob is a senior management executive with a demonstrable track record in the medical device sector. Over his extensive career Bob has been involved in the valuation, development, marketing, acquisition and sale of multiple medical devices. Bob has served as Head of Medical Device & Life Sciences Group for Acacia Research Group (NASDAQ) in the role of Senior Vice President, where he built the medical device business to $30 million in revenue. Previously he served as global chief IP counsel for Synthes Inc. (SIX) and Boston Scientific (NYSE) Endoscopy, both multi-billion-dollar companies, where he managed the medical products acquisition and licensing transactions along with other senior management roles. Bob has a bachelor’s degree in mechanical engineering and an MBA from the University of Massachusetts and a juris doctorate from the New Hampshire School of Law. Additionally, he is a registered patent attorney, a named inventor on 14 US patents and pending applications in the medical device sector and joint inventor of the X-PLO2R.
